<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875130</url>
  </required_header>
  <id_info>
    <org_study_id>PTE/8424-2/2020</org_study_id>
    <nct_id>NCT04875130</nct_id>
  </id_info>
  <brief_title>Adrenomedullin in Context With Pulmonary Embolism</brief_title>
  <official_title>Adrenomedullin in Context With the Diagnose of Pulmonary Embolism and Its Positive / Negative Predictive Value</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pulmonary embolism (PE) causes a blockade of the pulmonary arteries typical due to a&#xD;
      thrombus which is formed in the lower region of the body or pretty rare to other materials&#xD;
      (tumor, air, fat). The working group plans to evaluate the pathology of the thromboembolism&#xD;
      in the case of a partial, subtotal or even total pulmonary embolism. The acute PE is still&#xD;
      often in the adult population and in many accompanied by death. Etiological the problem&#xD;
      occurs through an acute right ventricular failure and leads into severe pulmonal perfusion&#xD;
      disorder with shock and hypoxemia. The right diagnose is pretty hard in the clinical day&#xD;
      because all symptoms are common and unspecific. To provide the best treatment in short time&#xD;
      it is needed to sum up all the symptoms and evaluate the risk of an acute pulmonary embolism&#xD;
      and it's morbidity.&#xD;
&#xD;
      The easiest and fastest way treating a PE is to apply a systemic intravenous thrombolysis but&#xD;
      bleeding complications are the most common and most frequently side effects. The&#xD;
      decision-making process in patients without shock is pretty hard because of having no clear&#xD;
      diagnose. Lab parameters and imaging (CT angiography) is important for the best decision in&#xD;
      critical ill PE patients but time is sometimes missing.&#xD;
&#xD;
      A possible new biomarker in identifying a PE is adrenomedullin.&#xD;
&#xD;
      Elevated adenomedullin levels in septic patients with left ventricular heart failure, severe&#xD;
      dyspnoea and intubated patients are well known, but in the case of PE it wasn't analysed yet.&#xD;
      Human adrenomedullin is a protein with 52 amino acid which is produced in the lung and first&#xD;
      extracted in the adrenal gland. The sequence homology is pretty similar to the&#xD;
      Calcitonin-Gene-Related-Peptide (CGRP)-protein superfamily (vasodilatation). Its precursor is&#xD;
      named pro-adrenomedullin peptide and it shows a significant weaker vasodilatation activity&#xD;
      compaired to adrenomedullin. Adrenomedullin causes severe hypotonia in scientific studies&#xD;
      where it was applied as an intravenous bolus or infusion. This vasodilatation effect concern&#xD;
      to the systemic and as well in the pulmonary circulation. Its vasodilatation mechanism is not&#xD;
      clarified yet.&#xD;
&#xD;
      The trial is defined as an prospective study, where the investigators would like to&#xD;
      measure/analyse the adrenomeulline level in PE patients in the intermediate high and high&#xD;
      risk population. The diagnose and treatment of the patients is fixed to the European Society&#xD;
      of Cardiology (ESC) recommendations of the cardiology society of 2019 Guidelines on Acute&#xD;
      Pulmonary Embolism (Diagnosis and Management of Pulmonary Embolism).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Is Adrenomedullin (ADM) a useful new biomarker in the diagnose of pulmonary embolism?</measure>
    <time_frame>admission - 5th day (change in the baseline)</time_frame>
    <description>Measurement: ADM-Kit (ELISA technique) measures the trend level. Additionally, the change of vital parameters/other blood results are examined e.g.:&#xD;
blood pressure&#xD;
pulse&#xD;
routine lab (Hb, erythrocytes, thrombocytes, leucocytes, etc.)&#xD;
Brain Natriuretic Peptide (BNP)/ N-terminale pro Brain Natriuretic Peptide (pro-NT-BNP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Is it possible to quantify the severity of pulmonary embolism, because of knowing the elevation of adrenomedullin in systemic circulation failure?</measure>
    <time_frame>through study completion (2 year)</time_frame>
    <description>Comparing CT-angiography imaging, clinical presentation and ADM-level to evaluate correlation between the ADM-level and the severity of the pulmonary embolism.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>confirmed pulmonary embolism</arm_group_label>
    <description>Patients with intermediate high and high risk of an acute pulmonary embolism with clinical symptoms.&#xD;
On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).&#xD;
Age under 18.&#xD;
Written agreement to the examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Taking blood samples (plasma, serum) and measure the level of Adrenomedullin</description>
    <arm_group_label>confirmed pulmonary embolism</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  emergency ward&#xD;
&#xD;
          -  cardial observation ward&#xD;
&#xD;
          -  internal medicine ward&#xD;
&#xD;
          -  intensive care ward&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with intermediate high and high risk of an acute pulmonary embolism with&#xD;
             clinical symptoms.&#xD;
&#xD;
          -  On image based procedures confirmed pulmonary embolism (TTE, contrast CT-angiography).&#xD;
&#xD;
          -  Written agreement to the examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18.&#xD;
&#xD;
          -  Missing written agreement or cancelled agreement on any time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lajos Bogár, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pécs - School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominik Hinterreiter, MD</last_name>
    <phone>+436603733643</phone>
    <email>D.Hinterreiter@gmx.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Mühl, MD</last_name>
    <phone>+3672535832</phone>
    <email>drdianamuhl@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KRAGES - Hospital of Oberwart</name>
      <address>
        <city>Oberwart</city>
        <state>Burgenland</state>
        <zip>7400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Hinterreiter, MD</last_name>
      <phone>+436603733643</phone>
      <email>D.Hinterreiter@gmx.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Pécs</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Mühl, MD</last_name>
      <phone>+3672535832</phone>
      <email>drdianamuhl@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://www.uptodate.com/contents/overview-of-acute-pulmonary-embolism-in-adults</url>
    <description>Pulmonary embolism in adults</description>
  </link>
  <results_reference>
    <citation>Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, Butler J. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail. 2019 Feb;21(2):163-171. doi: 10.1002/ejhf.1366. Epub 2018 Dec 28. Review.</citation>
    <PMID>30592365</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishikimi T, Nakagawa Y. Adrenomedullin as a Biomarker of Heart Failure. Heart Fail Clin. 2018 Jan;14(1):49-55. doi: 10.1016/j.hfc.2017.08.006. Epub 2017 Oct 7. Review.</citation>
    <PMID>29153200</PMID>
  </results_reference>
  <results_reference>
    <citation>Geven C, Kox M, Pickkers P. Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. Front Immunol. 2018 Feb 19;9:292. doi: 10.3389/fimmu.2018.00292. eCollection 2018. Review.</citation>
    <PMID>29520277</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Adrenomedullin</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

